<DOC>
	<DOCNO>NCT02856685</DOCNO>
	<brief_summary>This Phase 1/2 , open-label , multicenter study .</brief_summary>
	<brief_title>A Study Mitoxantrone Hydrochloride Liposome Infusion</brief_title>
	<detailed_description>The Phase 1 part study design identify MTD RP2D , characterize safety , tolerability , PK . The Phase 1 part study include 2 part : dose escalation dose expansion . After confirmation RP2D expansion part Phase 1 , enrolment Phase 2 part study begin . The primary objective Phase 2 part study evaluate efficacy investigational drug administer patient relapsed refractory NHL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Signed informed consent prior studyrelated procedure Patients histologically confirm , relapse refractory NHL treatment standard regimen . Patients intermediate aggressive subtypes ( example , diffuse large Bcell lymphoma , mantle cell lymphoma , peripheral Tcell lymphoma , anaplastic largecell lymphoma ) indolent subtypes require treatment ( example , follicular lymphoma , small lymphocytic lymphoma ) enrol Phase 1 part study ; Patients indolent type NHL must assess need treatment Investigator , base presence lymphomarelated symptom presence significant tumor burden ; ( Phase 1 ) Adult patient histologically confirm relapsed refractory aggressive NHL ( include diffuse large Bcell lymphoma , peripheral Tcell lymphoma , natural killer cell lymphoma ) treat standard regimen know effective therapy ; ( Phase 2 ) &gt; 4 week since last cycle chemotherapy prior study drug administration ; Recovered toxicity prior chemotherapy Investigator 's discretion ; Patients must Eastern Cooperative Oncology Group ( ECOG ) performance score 02 ; Patients sufficient baseline organ function whose laboratory data meet follow criterion enrolment : Absolute neutrophil count ≥ 1.5 x 109/L ; Platelets ≥ 75 x 109/L ; Hemoglobin ≥ 90 g/L ( unless bone marrow involvement present ) ; Liver function : Serum bilirubin ≤ 1.2 x upper limit normal ( ULN ) , Aspartate aminotransferase alanine aminotransferase ≤ 3 x ULN without liver metastasis ≤ 5 x ULN patient document liver metastasis ; International normalization ratio &lt; 1.3 patient anticoagulant &lt; 3 patient anticoagulant Serum creatinine ≤ 1.5 mg/dL estimate glomerular filtration rate &gt; 40 mL/min/m2 ; Left ventricular ejection fraction ( LVEF ) &gt; 50 % ; Life expectancy ≥ 12 week ; Women childbearing potential must negative pregnancy test prior study entry , agree use adequate contraception study entry least 3 month last dose study drug . Adequate method contraception patient partner include vasectomize partner ( least 6 month prior dose ) ; intrauterine device ; condom spermicidal gel , foam , cream , film , suppository ; diaphragm spermicidal gel , foam , cream , film , suppository ; cervical cap spermicidal gel , foam , cream , film , suppository.A female patient nonchildbearing potential must least 12 continuous month natural ( spontaneous ) amenorrhea , folliclestimulating hormone level &gt; 40 mIU/mL Screening , surgical bilateral oophorectomy hysterectomy &gt; 6 week prior Screening ; A male patient must agree use adequate contraception ( male condom spermicide ; sterile sexual partner ; female sexual partner use intrauterine device spermicide , female condom spermicide , contraceptive sponge spermicide , intravaginal system , diaphragm spermicide , cervical cap spermicide , oral , implantable , transdermal , injectable contraceptive ) study entry least 3 month last dose study drug ; Involved lymph node mass measurable least 2 perpendicular dimension &gt; 1.5 cm long perpendicular dimension ( base Cheson et al 2014 ) ( Additional Inclusion Criteria Phase 2 ) ; Agree undergo pretreatment bone marrow biopsy posttreatment bone marrow biopsy require confirm response ( Additional Inclusion Criteria Phase 2 ) . Pregnant breastfeeding woman ; Patients history allergy anthracyclines liposomal drug ; Prior treatment mitoxantrone ; Treatment doxorubicin total cumulative dose &gt; 300 mg/m2 , epirubicin total cumulative dose &gt; 500 mg/m2 ; Investigational treatment within 4 week start PLM60 ; Systemic chemotherapy within 4 week start PLM60 ; Radiotherapy ( ≥25 % bone marrow ) within 4 week start PLM60 ; Radio/toxinimmunoconjugates within 42 day start PLM60 ; Prior allogeneic stem cell transplantation ; Known central nervous system involvement NHL ; Patients follow type cardiac impairment time enrolment : New York Heart Association class III IV heart disease ; Uncontrolled angina , congestive heart failure , myocardial infarction within 6 month prior enrolment ; An LVEF echocardiogram multigated acquisition ( MUGA ) scan &lt; 50 % ; QT interval prolongation ( &gt; 450 m male , &gt; 470 ms female ) ; A past history cardiac disease cause anthracyclines ; History malignancy NHL past 3 year prior enrolment , except adequately treat nonmelanoma skin cancer situ cervical cancer ; Patients evidence active infection include follow : Patients treat antibiotic active infection time enrolment ; Patients evidence active hepatitis C chronic active hepatitis B ; Patients know diagnosis human immunodeficiency virus ( HIV ) infection/ acquire immunodeficiency syndrome ( AIDS ) ; Other severe poorly control illness circumstance would interfere evaluation key study endpoint would put patient risk participate study opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>